Benutzer: Gast  Login
Titel:

The anticancer drug imatinib induces cellular autophagy.

Dokumenttyp:
Journal Article; Research Support, Non-U.S. Gov't; Article
Autor(en):
Ertmer, A; Huber, V; Gilch, S; Yoshimori, T; Erfle, V; Duyster, J; Elsässer, HP; Schätzl, HM
Abstract:
The tyrosine kinase inhibitor imatinib (Gleevec, Novartis Pharmaceuticals Corporation; Basel, Switzerland) is a powerful drug for treatment of chronic myelogenous leukemia (CML) and other malignancies. It selectively targets various tyrosine kinases, thereby leading to growth arrest of respective cancer cells. Given its wide application, it is of high importance to know all related underlying molecular mechanisms. We had previously found that imatinib increases the cellular clearance of intrace...     »
Zeitschriftentitel:
Leukemia
Jahr:
2007
Band / Volume:
21
Heft / Issue:
5
Seitenangaben Beitrag:
936-42
Sprache:
eng
Volltext / DOI:
doi:10.1038/sj.leu.2404606
PubMed:
http://view.ncbi.nlm.nih.gov/pubmed/17330103
Print-ISSN:
0887-6924
TUM Einrichtung:
III. Medizinische Klinik und Poliklinik (Hämatologie / Onkologie); Institut für Virologie
 BibTeX